1 – 14 of 14
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(1). p.109-114(
- Contribution to journal › Article
- 2018
-
Mark
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
(
- Contribution to journal › Article
- 2011
-
Mark
Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
(
- Contribution to journal › Article
- 2007
-
Mark
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
(
- Contribution to journal › Article
- 2006
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
- 2004
-
Mark
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2003
-
Mark
Prolonged tamoxifen therapy; effects on contralateral breast cancer, endometrial cancer incidence and cardiovascular mortality
(
- Contribution to journal › Published meeting abstract
- 2000
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
- 1999
-
Mark
Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
- 1998
-
Mark
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
1998) In Annals of oncology : official journal of the European Society for Medical Oncology 9(4). p.403-411(
- Contribution to journal › Article
-
Mark
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide : prognostic and therapeutic implications
(
- Contribution to journal › Article